All In MedTech

Device Trial Radar · NCT07803679

A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma

A Phase 4, Open-label, Blinded Primary Endpoint, Randomized Multicenter Trial to Assess the Effectiveness of Evolocumab With Routine Lipid Management Compared With Routine Lipid Management Alone in Reducing the Plaque Burden in Patients With Subclinical Atheroma

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 308 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

308

Planned (sponsor's estimate)

Start

Jan 31, 2027

Primary completion

Apr 30, 2029

Study completion Apr 30, 2029

Sponsor

Lead sponsor
AmgenNot on our public-company list
Sponsor type
Industry
First posted
Sep 4, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this trial is to demonstrate that Evolocumab plus routine lipid management is superior to routine lipid management alone in modifying plaque (non-calcified) volume as measured by Artificial Intelligence-enabled Quantitative Coronary Plaque Analysis (AI-QCPA) from Coronary Computed Tomography Angiography (CCTA).

Conditions

  • Coronary Artery Disease
  • Hypercholesterolemia
  • Atheroma
  • Atherosclerotic Plaque

Interventions

  • EvolocumabDrug

    Evolocumab will be provided as a single-dose, prefilled AI pen for fixed dose subcutaneous (SC) injection.

  • Routine Lipid ManagementDrug

    Routine lipid management therapies will be administered at the discretion of the investigator per SoC.

  • AutoinjectorDevice

    AI for SC injection of Evolocumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Non-Calcified Plaque (NCP) Volume from Baseline to Week 72Time frame: From Baseline to Week 72

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.